Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 5,849 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $29.00, for a total value of $169,621.00. Following the completion of the sale, the executive vice president owned 67,828 shares of the company’s stock, valued at $1,967,012. This represents a 7.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ:ACAD opened at $29.21 on Friday. The firm has a market capitalization of $5.03 billion, a PE ratio of 13.16, a PEG ratio of 17.19 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 1-year low of $19.69 and a 1-year high of $29.48. The business’s 50 day moving average is $24.39 and its 200-day moving average is $23.27.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals’s revenue was up 16.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.16 earnings per share. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ACAD. Royal Bank Of Canada increased their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Wednesday. Citigroup reissued a “market outperform” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday. Oppenheimer increased their price target on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the stock a “market perform” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday. Finally, Canaccord Genuity Group lifted their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 29th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $33.44.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its stake in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 402 shares during the last quarter. Cetera Investment Advisers increased its position in shares of ACADIA Pharmaceuticals by 2.7% during the 4th quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock worth $437,000 after purchasing an additional 436 shares in the last quarter. J.W. Cole Advisors Inc. increased its position in shares of ACADIA Pharmaceuticals by 2.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 501 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in ACADIA Pharmaceuticals by 2.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 28,666 shares of the biopharmaceutical company’s stock valued at $766,000 after purchasing an additional 566 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.